BPC-157 in Humans: What Clinical Evidence Actually Exists

Short answer

Human evidence is very limited. Anyone looking for a clinical body comparable to a late-stage drug program will not find it here.

This page does not turn a pilot into a use guide. It does not reproduce an infusion regimen as an instruction. The aim is to show what is published, how small it is, and what cannot be concluded.

The question this page tries to answer — and that many pages avoid — is simple: how much of what is claimed about BPC-157 is human, how much is animal, and how much is assumption? The answer, today, is that verifiable human material is scarce.

Published human pilot evidence

Lee and Burgess published a 2025 pilot titled “Safety of Intravenous Infusion of BPC157 in Humans.” It appeared in Alternative Therapies in Health and Medicine. The sample size is two.¹

Two participants: a 58-year-old Asian man and a 68-year-old Caucasian woman, both with prior intravenous exposure to BPC-157. The design is open-label. The authors interpret the study in a safety key. That author interpretation is not adopted here as a general conclusion.¹

A small pilot involving two participants reported no measured adverse effects under the study conditions; the sample is far too small to establish general safety. One cannot write “BPC-157 has been shown safe in humans” from n = 2.¹

The study is not a tendon trial, not a colitis trial, and not an efficacy trial. It is an intravenous-infusion pilot in two people already exposed. Any administered quantities that appear in the original source stay in that source; they are not turned into practical instructions here.

An open-label pilot also does not resolve selection bias or expectancy. Without blinding and without a control, the absence of measured events is a descriptive fact about those two people under those conditions, not a population risk estimate.¹

Other claimed human evidence

Vasireddi and colleagues (2025), in an orthopedic review searching through 3 June 2024, identified 35 preclinical studies and one clinical study. That count matches this cluster’s reading: verifiable clinical material is scarce.³

Clinic stories, forums, and shops are not collected here. If it is not reliably published and verifiable, it does not enter as human evidence. Recovery anecdotes are not treated as data.

What does a sample of two tell us?

Very little about population-level safety or efficacy. With two people there is no statistical power for uncommon events, no generalization across sexes, ages, or comorbidities, and no control group that would let anyone attribute the absence of events to the peptide rather than to chance.¹

A sample of two also inherits selection: both participants had already received intravenous BPC-157. That does not represent an unexposed population.

No completed Phase II evidence

The 2026 review of BPC-157 as an investigational peptide therapeutic describes more than three decades of preclinical work and pharmaceutical development that remains rudimentary. It notes the lack of an approved formulation, a validated dosing regimen, and a completed Phase II trial.²

Without completed Phase II there is no intermediate clinical base for an efficacy claim in a human indication. The fact that a compounding committee discussed an ulcerative-colitis nomination in 2026 does not fill that gap.^4,2

“There is a human paper” should also not be confused with “there is a clinical program.” A two-person pilot and a long preclinical field can coexist. That coexistence is the current state, not an automatic transition toward approval.

What evidence would strengthen the case?

• Larger controlled studies with endpoints defined in advance.
• Prospective trial registration, so the protocol is visible before the results.
• Independent replication, outside a single author environment.
• Systematic safety assessment, not merely the absence of events in two people.
• A validated formulation and dosing regimen, which do not exist today.²

That would describe a more mature clinical program. It is not a prediction that approval is likely. This cluster does not speculate on the outcome of a development that, according to the 2026 review, remains rudimentary.²

For compound identity, What Is BPC-157. For FDA and WADA status, regulatory status. The map is the BPC-157 hub.